MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 204690 | Name: Buparlisib (BKM120)
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Buparlisib, also known as BKM120, is an orally bioavailable specific oral inhibitor of the pan-class I phosphatidylinositol 3-kinase (PI3K) family of lipid kinases with potential antineoplastic activity. PI3K inhibitor BKM120 specifically inhibits class I PIK3 in the PI3K/AKT kinase (or protein kinase B) signaling pathway in an ATP-competitive manner, thereby inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate and activation of the PI3K signaling pathway.

Chemical Structure

Buparlisib (BKM120)
Buparlisib (BKM120)
CAS#944396-07-0 (free base)

Theoretical Analysis

MedKoo Cat#: 204690

Name: Buparlisib (BKM120)

CAS#: 944396-07-0 (free base)

Chemical Formula: C18H21F3N6O2

Exact Mass: 410.1678

Molecular Weight: 410.39

Elemental Analysis: C, 52.68; H, 5.16; F, 13.89; N, 20.48; O, 7.80

Price and Availability

Size Price Availability Quantity
50mg USD 150.00 Ready to ship
100mg USD 250.00 Ready to ship
200mg USD 450.00 Ready to ship
500mg USD 950.00 Ready to ship
1g USD 1,650.00 Ready to ship
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
944396-07-0 (free base) 1312445-63-8 (HCl)
Synonym
NVPBKM120; NVP BKM120; NV- BKM120; BKM120; BKM-120; BKM 120; Buparlisib.
IUPAC/Chemical Name
5-[2,6-Di(4-morpholinyl)-4-pyrimidinyl]-4-(trifluoromethyl)-2-pyridinamine.
InChi Key
CWHUFRVAEUJCEF-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H21F3N6O2/c19-18(20,21)13-9-15(22)23-11-12(13)14-10-16(26-1-5-28-6-2-26)25-17(24-14)27-3-7-29-8-4-27/h9-11H,1-8H2,(H2,22,23)
SMILES Code
NC1=NC=C(C2=NC(N3CCOCC3)=NC(N4CCOCC4)=C2)C(C(F)(F)F)=C1
Appearance
white solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO.
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related: 944396-07-0 (free base) 1312445-63-8 (HCl). NVP-BKM120 is a selective pan class 1 PI3 Kinase inhibitor.  It was found that NVP-BKM120 inhibited the PI3 signaling pathways, leading to different forms of cell death based on P53 statuses. Further studies are warranted to determine if NVP-BKM120 has potential as a glioma treatment. (source: http://www.ncbi.nlm.nih.gov/pubmed/22065080 ).       
Biological target:
Buparlisib (BKM120; NVP-BKM120) is a pan-class I PI3K inhibitor, with IC50s of 52, 166, 116 and 262 nM for p110α, p110β, p110δ and p110γ, respectively.
In vitro activity:
The results demonstrated that the treatment of KG-1 with BKM120 not only inhibited proliferative capacity by reducing DNA replication and the number of viable cells but also led to an increased percentage of cells in the G2/M phase, suggesting that the antiproliferative effects of the inhibitor are mediated, at least partially, through the induction of G2/M arrest. In an investigation of the effects of PI3K suppression on multiple myeloma cells, the inhibitory effect of pan-PI3K inhibition on the survival of both KMM-1 and RPMI 8226 cells via the induction of SIRT1-mediated G2/M arrest was also highlighted. Among examples of overactivation of malignant signaling networks, and foremost of the PI3K pathway, the c-Myc oncogene is explicitly activated and subsequently leads to cell cycle progression via the inhibition of cell cycle-related genes such as p21 and p27 cyclin-dependent kinase inhibitors. Remarkably, while BKM120-induced G2/M arrest was associated with the upregulation of p21 and p27 expression, this study could find no noticeable alteration in c-Myc mRNA levels, suggesting the probable contribution of the c-Myc oncogene with less sensitivity of leukemic cells to the PI3K inhibitors. Accordingly, investigation of the effects of the small-molecule inhibitor of c-Myc revealed that 10058-F4 reduced KG-1 cell survival and sensitized the cells to lower concentrations of either BKM120 or idelalisib, supporting the hypothesis that the c-Myc inhibitors may restore leukemic cell sensitivity to PI3K inhibitors when administered as part of combination regimens. Reference: Turk J Haematol. 2020 Sep; 37(3): 167–176. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463220/
In vivo activity:
This study next used intracranial orthotopic allografts of PP (p53f/f;Ptenf/f ) GBM (glioblastoma) to examine BKM120 (also known as buparlisib; Table S1). BKM120 is currently the only pan-PI3K inhibitor with proven brain penetration and has been tested in the clinic for GBM patients. Treatment with BKM120 prolonged the median survival of PP-bearing mice slightly from 22 to 27 days (Figure 4A). While this result is statistically significant, it is unlikely to have a meaningful clinical impact. WB and IHC analyses of tumors harvested from experimental mice showed that BKM120 modestly reduced phosphorylation of both Akt and S6RP (Figures 4B and and4C),4C), suggesting that while BKM120 can cross the BBB, it cannot deeply suppress Akt-mammalian target of rapamycin (mTOR) signaling. Data are consistent with a recent clinical trial that showed that BKM120 does not effectively suppress S6RP phosphorylation despite adequate brain penetration and has limited efficacy in patients with GBM. Reference: Cell Rep. 2020 Sep 29; 32(13): 108196. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571617/
Solvent mg/mL mM
Solubility
DMSO 91.0 221.74
Ethanol 82.0 199.81
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 410.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Sadeghi S, Esmaeili S, Pourbagheri-Sigaroodi A, Safaroghli-Azar A, Bashash D. PI3K Abrogation Using Pan-PI3K Inhibitor BKM120 Gives Rise to a Significant Anticancer Effect on AML-Derived KG-1 Cells by Inducing Apoptosis and G2/M Arrest. Turk J Haematol. 2020 Aug 28;37(3):167-176. doi: 10.4274/tjh.galenos.2020.2019.0440. Epub 2020 Mar 12. PMID: 32160736; PMCID: PMC7463220. 2. Padthaisong S, Dokduang H, Yothaisong S, Techasen A, Namwat N, Yongvanit P, Khuntikeo N, Titapun A, Sangkhamanon S, Loilome W. Inhibitory effect of NVP-BKM120 on cholangiocarcinoma cell growth. Oncol Lett. 2018 Aug;16(2):1627-1633. doi: 10.3892/ol.2018.8848. Epub 2018 May 31. PMID: 30008846; PMCID: PMC6036373. 3. Xie S, Ni J, McFaline-Figueroa JR, Wang Y, Bronson RT, Ligon KL, Wen PY, Roberts TM, Zhao JJ. Divergent Roles of PI3K Isoforms in PTEN-Deficient Glioblastomas. Cell Rep. 2020 Sep 29;32(13):108196. doi: 10.1016/j.celrep.2020.108196. PMID: 32997991; PMCID: PMC7571617. 4. Li X, Martinez-Ledesma E, Zhang C, Gao F, Zheng S, Ding J, Wu S, Nguyen N, Clifford SC, Wen PY, Ligon KL, Yung WKA, Koul D. Tie2-FGFR1 Interaction Induces Adaptive PI3K Inhibitor Resistance by Upregulating Aurora A/PLK1/CDK1 Signaling in Glioblastoma. Cancer Res. 2019 Oct 1;79(19):5088-5101. doi: 10.1158/0008-5472.CAN-19-0325. Epub 2019 Aug 15. PMID: 31416846.
In vitro protocol:
1. Sadeghi S, Esmaeili S, Pourbagheri-Sigaroodi A, Safaroghli-Azar A, Bashash D. PI3K Abrogation Using Pan-PI3K Inhibitor BKM120 Gives Rise to a Significant Anticancer Effect on AML-Derived KG-1 Cells by Inducing Apoptosis and G2/M Arrest. Turk J Haematol. 2020 Aug 28;37(3):167-176. doi: 10.4274/tjh.galenos.2020.2019.0440. Epub 2020 Mar 12. PMID: 32160736; PMCID: PMC7463220. 2. Padthaisong S, Dokduang H, Yothaisong S, Techasen A, Namwat N, Yongvanit P, Khuntikeo N, Titapun A, Sangkhamanon S, Loilome W. Inhibitory effect of NVP-BKM120 on cholangiocarcinoma cell growth. Oncol Lett. 2018 Aug;16(2):1627-1633. doi: 10.3892/ol.2018.8848. Epub 2018 May 31. PMID: 30008846; PMCID: PMC6036373.
In vivo protocol:
1. Xie S, Ni J, McFaline-Figueroa JR, Wang Y, Bronson RT, Ligon KL, Wen PY, Roberts TM, Zhao JJ. Divergent Roles of PI3K Isoforms in PTEN-Deficient Glioblastomas. Cell Rep. 2020 Sep 29;32(13):108196. doi: 10.1016/j.celrep.2020.108196. PMID: 32997991; PMCID: PMC7571617. 2. Li X, Martinez-Ledesma E, Zhang C, Gao F, Zheng S, Ding J, Wu S, Nguyen N, Clifford SC, Wen PY, Ligon KL, Yung WKA, Koul D. Tie2-FGFR1 Interaction Induces Adaptive PI3K Inhibitor Resistance by Upregulating Aurora A/PLK1/CDK1 Signaling in Glioblastoma. Cancer Res. 2019 Oct 1;79(19):5088-5101. doi: 10.1158/0008-5472.CAN-19-0325. Epub 2019 Aug 15. PMID: 31416846.
1: Narimatsu S, Mizukami T, Huang Y, Masubuchi Y, Suzuki T. In-vitro metabolic interaction of bunitrolol enantiomers in rabbit liver microsomes. J Pharm Pharmacol. 1996 Nov;48(11):1185-9. doi: 10.1111/j.2042-7158.1996.tb03918.x. PMID: 8961170. 2: Tsuchihashi H, Aono J, Nagatomo T, Kawada T, Ohta H, Imai S. Effects of bunitrolol on adrenergic and serotonergic receptors. Jpn J Pharmacol. 1987 Nov;45(3):349-56. doi: 10.1254/jjp.45.349. PMID: 2893855. 3: Tsuchihashi H, Nagotomo T, Imai S. Selectivity of bunitrolol for beta 1- and beta 2-adrenergic receptors and 5HT1B-receptors: assessment by biphasic Scatchard plots and biphasic displacement curve analysis with 125I-iodocyanopindolol and 3H-CGP12177. Jpn J Pharmacol. 1989 Jun;50(2):93-100. doi: 10.1254/jjp.50.93. PMID: 2570175. 4: Chiba K, Hayase N, Ichihara K. Effects of bunitrolol on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Apr;82(4):384-8. doi: 10.1002/jps.2600820410. PMID: 8096874. 5: Ono S, Tsutsui M, Gonzalez FJ, Satoh T, Masubuchi Y, Horie T, Suzuki T, Narimatsu S. Oxidative metabolism of bunitrolol by complementary DNA-expressed human cytochrome P450 isozymes in a human hepatoma cell line (Hep G2) using recombinant vaccinia virus. Pharmacogenetics. 1995 Apr;5(2):97-102. doi: 10.1097/00008571-199504000-00006. PMID: 7663534. 6: Ishida R, Fujita S, Suzuki T. Bunitrolol metabolism and its inhibition by cimetidine. J Pharm Pharmacol. 1988 Jan;40(1):64-5. doi: 10.1111/j.2042-7158.1988.tb05155.x. PMID: 2896780. 7: Matsuzaki J, Yamamoto C, Miyama T, Takanaga H, Matsuo H, Ishizuka H, Kawahara Y, Kuwano M, Naito M, Tsuruo T, Sawada Y. Contribution of P-glycoprotein to bunitrolol efflux across blood-brain barrier. Biopharm Drug Dispos. 1999 Mar;20(2):85-90. doi: 10.1002/(sici)1099-081x(199903)20:2<85::aid- bdd159>3.0.co;2-3. PMID: 10206323. 8: Narimatsu S, Masubuchi Y, Hosokawa S, Ohmori S, Kitada M, Suzuki T. Involvement of a cytochrome P4502D subfamily in human liver microsomal bunitrolol 4-hydroxylation. Biol Pharm Bull. 1994 Jun;17(6):803-7. doi: 10.1248/bpb.17.803. PMID: 7951142. 9: Haddad S, Poulin P, Funk C. Extrapolating in vitro metabolic interactions to isolated perfused liver: predictions of metabolic interactions between R-bufuralol, bunitrolol, and debrisoquine. J Pharm Sci. 2010 Oct;99(10):4406-26. doi: 10.1002/jps.22136. PMID: 20310018. 10: Satoh K, Nunoki K, Goto T, Taira N. The mechanism underlying the vasodilator action of bunitrolol: contribution of alpha 1-adrenoceptor blocking action. J Cardiovasc Pharmacol. 1985 May-Jun;7(3):508-15. doi: 10.1097/00005344-198505000-00015. PMID: 2410682. 11: Narimatsu S, Kato R, Horie T, Ono S, Tsutsui M, Yabusaki Y, Ohmori S, Kitada M, Ichioka T, Shimada N, Kato R, Ishikawa T. Enantioselectivity of bunitrolol 4-hydroxylation is reversed by the change of an amino acid residue from valine to methionine at position 374 of cytochrome P450-2D6. Chirality. 1999;11(1):1-9. doi: 10.1002/(SICI)1520-636X(1999)11:1<1::AID-CHIR1>3.0.CO;2-E. PMID: 9914647. 12: Keul J, Lehmann M, Wybitul K. Zur Wirkung von Bunitrolol auf Herzfrequenz, metabolische Grössen bei Körperarbeit und Leistungsverhalten [Effect of bunitrolol on heart rate, metabolic parameters during physical exercise, and performance]. Arzneimittelforschung. 1981;31(11):1948-53. German. PMID: 6119096. 13: Takeda N, Nakamura I, Hatanaka T, Ohkubo T, Nagano M. Effects of bunitrolol on myocardial contractility and left ventricular myosin isoenzyme pattern. Arzneimittelforschung. 1988 Sep;38(9):1280-2. PMID: 2906244. 14: Pozenel H. Vergleichende ergometrische Untersuchungen nach Anwendung von Practolol und Bunitrolol [Comparable ergometric examinations before and after administration of practolol and bunitrolol (author's transl)]. Wien Klin Wochenschr. 1975 Jan 10;87(1):19-25. German. PMID: 236621. 15: Okabayashi T, Naito S, Arakawa K. Antihypertensive effect of intravenously and orally administered bunitrolol (Kö 1366). Arzneimittelforschung. 1979;29(9):1417-21. PMID: 42418. 16: Jonker JJ, de Klerk J, den Ottolander GJ. A double blind cross-over comparison of bunitrolol and placebo in the treatment of angina pectoris. Arzneimittelforschung. 1981;31(7):1140-2. PMID: 6115654. 17: Beumer HM, Ritter W. Antagonism of fenoterol against beta-blocking drugs bunitrolol and practolol in asthmatics. Respiration. 1975;32(5):363-7. doi: 10.1159/000193666. PMID: 241102. 18: Lund-Johansen P. Central haemodynamic effects of beta blockers in hypertension. A comparison between atenolol, metoprolol, timolol, penbutolol, alprenolol pindolol and bunitrolol. Eur Heart J. 1983 Jul;4 Suppl D:1-12. doi: 10.1093/eurheartj/4.suppl_d.1. PMID: 6137366. 19: Nagakura A, Kohei H. Simultaneous determination of bunitrolol and its metabolite in biological fluids, plasma and urine. J Chromatogr. 1982 Oct 8;232(1):137-43. doi: 10.1016/s0378-4347(00)86016-8. PMID: 6128351. 20: Banim SO, da Silva A, Balcon R. Haemodynamic observations with KO. 1366 (bunitrolol), a new beta-adrenergic blocking agent. Curr Med Res Opin. 1977;4(9):630-4. doi: 10.1185/03007997709115282. PMID: 22426.